http://graphenefrontiers.com Confidential and Proprietary
Biosensors: $21B Medical biosensors play a major role in improving patients' quality of life. Global Medical Biosensors market forecasted to grow at CAGR 10.16% 2013-2018
Problem 1st Gen POC Diagnostics: Not Good Enough • Limited Sensitivity • Slow • Inaccurate
Next Gen POC Diagnostics: Quantum Leap Confidential and Proprietary
Graphene Field Effect Transistor (GFET) chips and Reader Device
Devices: GFET GFET = Graphene Field Effect Transistor Confidential and Proprietary
Nobel Prize in Physics 2010
Confidential and Proprietary
GF SIX BIOSENSOR PLATFORM ELISA GFET 100x- 1000x better Limit of Detection (LOD) 1-20pg/ml than ELISA Ability to Multiplex No (1 antibody per run) Yes May take hours for Speed Sample to results in minutes incubation and processing Cost Expensive Optical Readers All electronic, lower cost After sample obtained, Ease of Use Trained Lab Tech Needed the rest is automated Relies on secondary Specific and direct Specificity of detection detection antibody detection – all electronic Higher false positives
Graphene Frontiers Biosensors and IoT GF Biosensors will transform healthcare and enable: • Healthcare technology growth • Healthcare connectivity • Epidemiology studies at national level • Big Data analytics
Graphene Frontiers Biosensors and IoT GF Biosensors will enable: (continued) • Connection to CDC and generate alerts when infectious diseases arise in certain areas • Easy and affordable diagnostics in rural areas • Connection between small clinics and large medical centers to treat difficult diseases
Mike Patterson, CEO mike@graphenefrontiers.com Victoria Tsai, SVP Business Development and Tech R&D victoria@graphenefrontiers.com http://graphenefrontiers.com Confidential and Proprietary
Recommend
More recommend
